Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
TSNA3339
- Development stage
- Preclinical
- Lead developer
- Taili Biotechnology
- Modality
- Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics
- Administration
- Intravenous
01
Overview
TSNA3339 is a preclinical-stage antibody-drug conjugate (ADC) being developed by Taili Biotechnology (Tyligand). The molecule consists of a monoclonal antibody targeting the epidermal growth factor receptor (EGFR) conjugated to a payload that acts as a KRAS G12D inhibitor. This therapeutic strategy aims to utilize EGFR as a cell-surface anchor to internalize the KRAS inhibitor, thereby overcoming the challenges of targeting intracellular KRAS G12D mutations. TSNA3339 is currently being investigated for the treatment of KRAS G12D-mutant solid tumors, including non-small cell lung cancer, pancreatic cancer, and colorectal cancer. The developer expects to submit an Investigational New Drug (IND) application in the first quarter of 2027.
- Other names
- TSNA3339TSNA-3339TSNA 3339
02
Targets
KRASG12D (Kirsten rat sarcoma viral oncogene homolog (KRAS) G12D mutant)EGFR T790M (Epidermal growth factor receptor T790M mutant)
Beyond the preview
Go deeper on TSNA3339.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on TSNA3339.